CN107106583B - Pharmaceutical compositions comprising acarbose and their use for immunomodulation - Google Patents
Pharmaceutical compositions comprising acarbose and their use for immunomodulation Download PDFInfo
- Publication number
- CN107106583B CN107106583B CN201580063655.6A CN201580063655A CN107106583B CN 107106583 B CN107106583 B CN 107106583B CN 201580063655 A CN201580063655 A CN 201580063655A CN 107106583 B CN107106583 B CN 107106583B
- Authority
- CN
- China
- Prior art keywords
- acarbose
- day
- mice
- disease
- cia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 title claims abstract description 51
- 229960002632 acarbose Drugs 0.000 title claims abstract description 51
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 230000002519 immonomodulatory effect Effects 0.000 title description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 48
- 239000004012 Tofacitinib Substances 0.000 claims description 14
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 14
- 229960001350 tofacitinib Drugs 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 5
- 238000007910 systemic administration Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 19
- 208000027866 inflammatory disease Diseases 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 201000004681 Psoriasis Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 16
- 229960002751 imiquimod Drugs 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 13
- 201000004624 Dermatitis Diseases 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002955 immunomodulating agent Substances 0.000 description 7
- 229940121354 immunomodulator Drugs 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 229940123464 Thiazolidinedione Drugs 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 5
- 210000000544 articulatio talocruralis Anatomy 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- -1 biomolecules Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000000495 immunoinflammatory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 229940039887 tofacitinib 5 mg Drugs 0.000 description 4
- 206010000349 Acanthosis Diseases 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
- 206010051728 Bone erosion Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 108010016648 Immunophilins Proteins 0.000 description 3
- 102000000521 Immunophilins Human genes 0.000 description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007112 pro inflammatory response Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- QVNZBDLTUKCPGJ-SHQCIBLASA-N (2r)-2-[(3r)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-n-hydroxy-4-methylpentanamide Chemical compound O=C1N([C@H](CC(C)C)C(=O)NO)CC[C@@]1(N)C(C=C1)=CC=C1OCC1=CC(C)=NC2=CC=CC=C12 QVNZBDLTUKCPGJ-SHQCIBLASA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- JBNWDYGOTHQHOZ-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 JBNWDYGOTHQHOZ-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- OKRSVUYYCJPECG-LFGMFVMYSA-N 5α-hydroxytriptolide Chemical compound O=C1OCC([C@]2(O)C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 OKRSVUYYCJPECG-LFGMFVMYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015153 Erythema annulare Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 201000005708 Granuloma Annulare Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 206010052443 Myofascitis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940086290 acarbose 50 mg Drugs 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 229950005521 doramapimod Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000021403 epidermal cell division Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229950003168 merimepodib Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- KYLIMUJRJDIPPF-UHFFFAOYSA-N trisalicylate Chemical compound O=C1OC2=CC=CC=C2C(=O)OC2=CC=CC=C2C(=O)OC2=CC=CC=C12 KYLIMUJRJDIPPF-UHFFFAOYSA-N 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition comprising acarbose and its use for the preparation of a medicament for the treatment of an immune inflammatory disorder.
Description
Technical Field
The present invention relates to a novel use of acarbose, in particular for modulating immunity or treating immune inflammatory disorders.
Background
Immune inflammation is characterized by the inappropriate activation of the body's immune response. The immune system attacks and damages the body's own tissues or transplanted tissues without attacking infected foreign bodies. The tissues attacked by the immune system vary with disease. For example, in multiple sclerosis, the immune response is against nervous tissue, while crohn's disease is against the digestive tract. Immunoinflammatory disorders afflict millions of people and include conditions such as asthma, allergic intraocular inflammation, arthritis, atopic dermatitis, atopic eczema, diabetes, hemolytic anemia, inflammatory dermatitis, inflammatory bowel or gastrointestinal disorders (e.g., crohn's disease and ulcerative colitis), multiple sclerosis, myasthenia gravis, pruritus/inflammation, psoriasis, rheumatoid arthritis, cirrhosis, and systemic lupus erythematosus.
Many drugs have been developed for immune inflammatory diseases, but these drugs have different effects and often have undesirable side effects. Thus, there is a need for better therapeutic agents and methods for the treatment of immunoinflammatory disorders.
Disclosure of Invention
In view of the above problems, the inventors of the present invention have surprisingly found that known drug for treating type ii diabetes, acarbose, which is a glucosidase inhibitor drug, can perform reversible competitive inhibition with α -glucosidase on villi of small intestine to slow down the decomposition of saccharides in small intestine, thereby delaying the absorption of saccharides to avoid the phenomenon of postprandial hyperglycemia and achieve smoother postprandial glycemic control; the experiment of the invention shows that the medicine has the function of regulating immunity and can be used for treating immune inflammatory diseases.
Accordingly, in one aspect, the present invention provides a pharmaceutical composition for treating an immunoinflammatory disorder, comprising acarbose (acarbose).
In one embodiment of the present invention, the immune inflammatory disorder is: rheumatoid arthritis, psoriasis, type I diabetes, adult human Schneider's disease, neuromyelitis optica, Crohn's disease, ulcerative colitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, atopic dermatitis, multiple sclerosis, myasthenia gravis, psoriasis, ankylosing spondylitis, cirrhosis, or psoriatic arthritis.
In a preferred embodiment of the present invention, the pharmaceutical composition of the present invention may further comprise a second drug; wherein the second drug is preferably selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, biomolecules, immunomodulators, small molecule immunomodulators, disease modifying antirheumatic drugs (DMARDs), xanthines, anticholinergic compounds, beta receptor synergists, bronchodilators, nonsteroidal immunoaffinity protein dependent immunosuppressants, vitamin D analogs, psoralens, vitamin A acid and 5-aminosalicylic acid. In a more preferred embodiment, the disease modifying antirheumatic drug (DMARD) is tofacitinib (tobatinib).
In the embodiments of the present invention, the pharmaceutical composition may be in any dosage form, preferably in the form of a tablet or capsule. In another preferred embodiment, the pharmaceutical composition is formulated for local administration or systemic administration.
Another aspect of the invention is the use of acarbose for the preparation of an immunomodulatory drug.
Drawings
FIG. 1A: a graph showing the comparison of the incidence of CIA in the experimental group and the control group of CIA mice;
FIG. 1B: a graph showing the comparison of the number of the affected soles in the CIA mouse experimental group and the control group;
FIG. 1C: showing the sole photograph in the CIA mouse experimental group and the control group;
FIG. 1D: a graph showing the comparison of arthritis scores in the CIA mouse experimental group and the control group;
FIG. 1E: shows histology (H & E) photographs of ankle joints in the CIA mouse experimental group and the control group;
FIG. 1F: a histological comparison chart showing infiltration of inflammatory cells, synovial hyperplasia and bone erosion of ankle joints in the CIA mouse experimental group and the control group;
FIG. 2A: showing the content of selective cell hormone in the sole tissue in the CIA mouse experimental group and the control group by ELISA measurement;
FIG. 2B: showing the content of selective cell hormone in serum in the CIA mouse experimental group and the control group by ELISA;
FIG. 3A: shows a graph comparing anti-CII IgG in the CIA mouse experimental group and the control group;
FIG. 3B: a graph showing the comparison of CII antigen-stimulated proliferation in the CIA mouse experimental group and the control group;
FIG. 3C: a graph showing comparison of different cytokine contents of lymphocyte supernatants in the CIA mouse experimental group and the control group;
FIG. 4A is a graph comparing the efficacy evaluation of tofacitinib at 1mg/kg/day, 5mg/kg/day, and 25mg/kg/day doses in CIA mice;
FIG. 4B: a comparison graph of efficacy evaluation of 1mg/kg/day tofacitinib, 500mg/kg/day acarbose and 1mg/kg/day tofacitinib on CIA mice;
FIG. 4C: a comparison graph of efficacy evaluation of tofacitinib 5mg/kg/day, acarbose 500mg/kg/day combined with tofacitinib 5mg/kg/day on CIA mice;
FIG. 5A: a photograph showing skin photographs of an experimental group and a control group for inducing psoriasis in mice with imiquimod 62.5mg/kg/day and treated with acarbose 500 mg/kg/day;
FIG. 5B: shows a graph comparing clinical characterization scores of an experimental group induced by imiquimod 62.5mg/kg/day in mice psoriasis and treated with acarbose 500mg/kg/day with a control group;
FIG. 6A: control cream induced psoriasis mice skin histology (H & E) photographs;
FIG. 6B: photographs of mouse skin histology (H & E) with imiquimod-induced psoriasis;
FIG. 6C: photographs of mouse skin histology (H & E) treated with imiquimod-induced psoriasis and acarbose 50 mg/kg/day;
FIG. 6D: mouse skin histology (H & E) photographs were treated with imiquimod-induced acarbose dry tinea 50 mg/kg/day.
Detailed Description
Hereinafter, exemplary embodiments and examples of the present invention will be described in detail with reference to the accompanying drawings so that the concept of the invention can be easily carried out by those skilled in the art.
It should be noted, however, that the present disclosure is not limited to the embodiments of the disclosure, and can be implemented in various ways. In the drawings, the parts not directly related to the present invention are omitted to enhance the clarity of the drawings, and reference numerals are labeled in the documents.
Non-limiting and non-exhaustive embodiments are described below with reference to fig. 1A-6D. It is to be understood that the drawings are merely illustrative of several embodiments in accordance with the disclosure of the present specification and that, therefore, the scope of the invention is not to be limited thereto, since the disclosure of the present invention will be described with particular detail in connection with the drawings.
The use of the terms "comprising" or "including" throughout this specification is intended to mean that one or more other components, steps, instructions for operation, and/or the presence or addition of elements are not excluded in addition to the described components, steps, instructions for operation, and/or elements. The use of the terms "about" or "approximately" means having a close or allowable error range for avoiding the illegal or improper use of the disclosed precise or absolute values by unknown third parties. The words "a" or "an" mean that the grammatical object of the article is one or more than one (e.g., at least one).
The present invention provides a pharmaceutical composition for the treatment of an immunoinflammatory disorder, comprising acarbose (acarbose), and the use of acarbose for the preparation of an immunomodulatory medicament.
The term "treating" as used herein means administering or prescribing a composition to a patient for treating or preventing an immune inflammatory disorder. By "patient" herein is meant any animal (e.g., a human). Other animals that may be treated with the methods, compositions, and kits of the invention include horses, dogs, cats, pigs, goats, rabbits, hamsters, monkeys, guinea pigs, rats, mice, lizards, snakes, sheep, cattle, fish, and birds.
The term "immunoinflammatory disorder" as used herein includes a number of conditions including, but not limited to, autoimmune diseases, proliferative skin disorders, and inflammatory eczema. Immune inflammatory disorders can result in destruction of healthy tissues of the body by the inflammatory process, loss of control of the immune system, and undesirable cell proliferation. Immune inflammatory disorders such as acne vulgaris; acute dyspnea syndrome; addison's disease; allergic rhinitis; allergic intraocular inflammatory disorders, ANCA-related small-vessel vasculitis; ankylosing spondylitis; arthritis, asthma; atherosclerosis; atopic dermatitis; autoimmune hemolytic anemia; autoimmune hepatitis; behcet's disease; Bell's palsy; bullous pemphigoid (bullous pemphigoid); cerebral ischemia; chronic obstructive pulmonary disease; cirrhosis of the liver; cogan's syndrome; contact skin diseases; COPD; crohn's disease; cushing's syndrome; dermatomyositis; diabetes mellitus; round lupus erythematosus; eosinophilic myofascitis; erythema nodosum; exfoliative dermatitis; fibromyalgia; glomerulosclerosis; giant cell arteritis; gout; gouty arthritis; (ii) graft-versus-host disease; eczema of the hand; allergic purpura (Henoch-Schonlein purpura); herpes gestationis (herpes geostationnis); hirsutism; idiopathic gonio-scleritis; idiopathic pulmonary fibrosis; idiopathic thrombocytopenic purpura; inflammatory bowel or gastrointestinal diseases, inflammatory skin diseases; lichen planus; lupus nephritis; lymphangiomatous tracheobronchitis; macular edema; multiple sclerosis; myasthenia gravis; myositis; osteoarthritis; pancreatitis; dermatitis-like rash; common aphtha; polyarteritis nodosa; polymyalgia rheumatica; scrotal pruritus; pruritus/inflammation; psoriasis; arthritis with dry tinea; rheumatoid arthritis; recurrent multiple chondritis; rosettes caused by sarcoidosis; rosettes caused by scleroderma; rosettes caused by the Schweiter's syndrome; rosettes due to systemic lupus erythematosus; rosettes due to urticaria; rosettes with rash-related pain; sarcoidosis; scleroderma; local glomerulosclerosis; septic shock syndrome; tendonitis or bursitis; syndrome of Sjogren's; schneisseria (Still's) disease; stroke-induced brain cell death; steve's disease; systemic lupus erythematosus; systemic sclerosis; takayasu's arteritis; temporal arteritis; toxic skin necrosis; pulmonary tuberculosis; type I diabetes; ulcerative colitis; uveitis; vasculitis; and Wegener's cysts. In preferred embodiments, the immune inflammatory disorder comprises rheumatoid arthritis, psoriasis, type I diabetes, adult human Schlemm's disease, neuromyelitis optica, Crohn's disease, ulcerative colitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, atopic dermatitis, multiple sclerosis, myasthenia gravis, psoriasis, ankylosing spondylitis, cirrhosis or psoriatic arthritis, or other immune inflammatory disorders associated with cytokine IL-17 dysregulation.
The term "non-skin inflammatory disorder" as used herein includes, for example, rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease.
The term "skin inflammatory disorder" or "inflammatory dermatitis" herein includes, for example, psoriasis, acute heat-toxicity dermatosis, eczema (e.g., acanthosis, miliaria, eczema of the palmoplantar, palmoplantar palmaris, plasmocytotic regional balanitis, balanoposthitis, Behcet's disease, erythema annulare, erythema durans, erythema multiforme, granuloma annulare, lichen glossum, lichen planus, lichen sclerosus atrophaeus, lichen simplex chronicus, lichen microtuberculus, pouchitis, pyoderma gangrenosum, sarcoidosis, suberinosis, urticaria and transient acanthosis. "proliferative skin disease" means benign or malignant disease characterized by an acceleration of epithelial or epidermal cell division. Examples of proliferative skin disorders are psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, basal and squamous cell skin cancers, scaly ichthyosis, epidermal laxity hyperkeratosis, pre-malignant keratosis, acne and seborrheic dermatitis. It will be appreciated by those skilled in the art that a particular disease, disorder or condition can be characterized as both proliferative skin disorders and inflammatory eczema. An example of such a disease is psoriasis.
The pharmaceutical composition of the present invention may further comprise a second drug. Wherein the second drug is preferably selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, biomolecules, immunomodulators, small molecule immunomodulators, disease modifying antirheumatic drugs (DMARDs), xanthines, anticholinergic compounds, beta receptor synergists, bronchodilators, nonsteroidal immunoaffinity protein dependent immunosuppressants, vitamin D analogs, psoralens, vitamin A acid and 5-aminosalicylic acid.
The term "non-steroidal anti-inflammatory drug" as used herein includes, but is not limited to, naproxen sodium, diclofenac potassium, aspirin, sulindac, diflunisal, piroxicam, tiometacin, ibuprofen, nabumetone, choline trisalicylate magnesium, sodium salicylate, salicylic acid-based salicylic acid (magnesium trisilalate), fenoprofen, flurbiprofen, ketoprofen, meclofenamate sodium, meloxicam, oxaprozin, sulindac, and tolmetin.
The term "disease modifying antirheumatic" as used herein includes, but is not limited to, carcinostatic (Methotrexate), Azathioprine (Azathioprine), Leflunomide (Leflunomide), Sulfasalazine (Sulfasalazine), Hydroxychloroquine (hydroxhloroquine), tofacitinib (Tobactinib).
The term "immunomodulator" herein includes, but is not limited to, Cyclosporin (cyclosporine), imiquimod (imiquimod).
The term "antihistamine" as used herein refers to a compound that blocks the action of histamine. Antihistamines types include, but are not limited to, ethanolamine, ethylenediamine, phenothiazine, alkylamine, piperazine, and piperidine.
The term "non-steroidal immunophilin-related immunosuppressant" or "NsIDI" as used herein refers to any non-steroidal agent that decreases pro-inflammatory cytokine production or secretion, binds to immunophilins, or causes down-regulation of the pro-inflammatory response. NsIDI includes calcineurin (calcidin) inhibitors such as cyclosporine, heparin (tacrolimus), ascomycin, pimecrolimus and other agents (peptides, peptide fragments, chemically modified peptides or peptidomimetic mimetics) that inhibit the phospholipase activity of calcineurin. NsIDI also includes rapamycin (rapamycin) (sirolimus) and everolimus (everolimus), which bind to FK 506-binding protein, FKBP-12 and block antigen-induced proliferation of white blood cells and cytokine secretion.
The term "small molecule immunomodulator" herein means a non-steroidal, non-NsIDI compound that can reduce pro-inflammatory cytokine production or secretion, leading to down-regulation of the pro-inflammatory response, or modulate the immune system in an immunophilin-independent manner. Examples of small molecule immunomodulators are p38MAP kinase inhibitors such as VX 702(Vertex Pharmaceuticals), SCIO 469(Scios), Doramamo (doramapimod) (Boehringer Ingelheim), RO 30201195(Roche) and SCIO323(Scios), TACE inhibitors such as DPC 333(Bristol Myers Squibb), ICE inhibitors such as Pracanthus (pranalcasan) (Vertex Pharmaceuticals), IMPDH inhibitors such as mycophenolate (mycophenolate) (Roche) and Melisson's patch (merimepodib) (Vertex Pharmaceuticals).
The dosage of the pharmaceutical composition of the present invention can be adjusted to the condition of the patient according to the skilled person, to provide a sufficient amount of the active ingredient, or alternatively, a low dose, a medium dose or a high dose can be selected. The effect of the administered dose can be judged by the skilled practitioner using any standard method appropriate to the intended indication.
The term "low dose" herein means at least 5% (e.g., at least 10%, 20%, 50%, 80%, 90% or even 95%) lower than the minimum standard recommended dose for a particular compound (administered by a given route to treat any human condition), e.g., a low dose of corticosteroid administered by inhalation is different from a low dose of corticosteroid administered orally.
The term "high dose" herein means at least 5% (e.g., at least 10%, 20%, 50%, 100%, 200%, or even 300%) higher than the highest standard recommended dose of a particular compound (for treating any human condition). By "middle dose" is meant a dose that is between the low and high doses.
The term "sufficient amount" as used herein means the combined amount of the compounds of the present invention that is required to treat or prevent immune inflammation in a clinically relevant manner. The sufficient amount of the active compound for carrying out the invention for the treatment of diseases due to immunoinflammation will vary depending on the mode of administration, the age, weight and general health of the patient.
Routes of administration for embodiments of the pharmaceutical compositions of the present invention include, but are not limited to, topical administration, transdermal and systemic administration (e.g., intravenous, intramuscular, inhalation, intrarectal, cervical, vaginal, intraperitoneal, intraarticular, ophthalmic or oral administration). Any of the foregoing routes of administration may be administered with conventional drugs for the treatment of immune inflammatory disorders.
The pharmaceutical composition of the present invention may be in any form, such as a tablet, capsule, pill, powder, granule, suspension, emulsifier, solution, gel (including hydrogel), paste, ointment, cream, plaster, infusion, osmotic delivery vehicle, suppository, enema, injection, implant, spray or aerosol. The compositions may be formulated according to conventional pharmaceutical practice, with oral dosage forms such as tablets, capsules, or syrups being preferred; or for rectal administration, such as suppositories; or other dosage forms, such as sustained release or sustained release dosage forms, etc.
In the pharmaceutical compositions of the present invention, if a second agent is included, each compound can be formulated by methods known in the art. For example, the first and second agents may be formulated simultaneously or separately. Preferably, the first and second agents are administered together at or near the same time; if administered simultaneously, they may be formulated together in the same pill, capsule, liquid, etc. By using different formulation strategies for different agents, the pharmacokinetic profiles of each agent can be appropriately matched. The individually or separately formulated medicaments may be packaged together in a kit. Non-limiting examples of the kit include 2 pills, one pill and powder, suppository and one liquid in a bottle, 2 external creams, etc. The kit may include optional accessories that assist in administering unit doses to a patient, including, for example, vials for infusion powder types, syringes, custom IV delivery systems, inhalants, and the like. In addition, the unit dose kit may include instructions for preparing and administering the composition. The kit can be manufactured as a single dose for one patient, multiple doses for a particular patient (either the same dose or individual compounds that differ in their potency as treatment progresses); or the kit may comprise multiple doses ("big pack") suitable for administration to multiple patients. The kit may be incorporated into a carton, blister pack, bottle, tube, or the like. Alternatively, controlled release and/or sustained release may be formulated, which means that the therapeutically active ingredient is released from the formulation at a controlled rate such that the ingredient maintains therapeutically effective blood levels (below toxic levels) over an extended period of time (e.g., about 12-24 hours), thus allowing for a 12 hour or 24 hour dosage form.
Examples
The present disclosure will hereinafter be described more particularly with reference to the examples and drawings. However, the disclosure is not limited to the examples and drawings.
Example 1 statistical investigation of the relationship between rheumatoid arthritis and acarbose
[ control study with population as the base case ]
The data source was a matched case control study using National Health Insurance Research Database (NHIRD)1999-2011 from taiwan as a population basis. NHIRD is a comprehensive encrypted medical data for more than 98% of taiwan population, and was released for research purposes. The NHIRD randomly picked millions of participants in 2000 to form a representative database containing potentially disabling autoimmune diseases, including Rheumatoid Arthritis (RA). The diagnosis of RA was further verified by the American society for rheumatology, RA classification Standard (1987).
[ study sample ]
Diabetic (DM) case
Patients who were initially diagnosed with diabetes on day 1/2000 [ international classification of disease, ninth revision, clinical revision (ICD9-CM) code 250.x ] and were prescribed any antidiabetic drug for more than 28 days were classified as DM patients. The DM diagnosis date is used to measure the time of progression of DM and is defined as the time of initial antidiabetic drug prescription.
Rheumatoid Arthritis (RA) cases
To determine that 24,429 patients with significant impairment syndrome (age ≧ 16 at the time of RA diagnosis) were newly diagnosed with RA between 2001 and 2010, patients with RA within one year of the beginning of antidiabetic therapy were excluded in order to minimize the possibility of anti-causal relationship. Among these RA patients, 723 patients were determined to have a history of diabetes of at least one year before the date of RA for the first diagnosis (index date).
Non-rheumatoid arthritis (non-RA) control group
Using KHID20000, RA diagnosis ages (16-25, 26-35, 36-45, 46-55, 56-65 or >65 years), gender and index year (index year) were matched for RA cases, and 7,230 DM patients with a history of DM over one year and never diagnosed RA as a non-RA control group were randomly selected in 1999-2011. The first clinic time was selected as the index date for the control group.
[ use of antidiabetic agent ]
Based on the prescribed record of NHIRDs, those using acarbose, metformin, Thiazolidinedione (TZD), insulin or sulfonylurea/glactin for 28 or more days a year before the day of the index are classified as acarbose users, metformin users, TZD users, insulin users or sulfonylurea/glactin users, respectively. Acarbose users are further classified into high dose users and low dose users according to the median annual cumulative dose.
[ potential interference factors ]
Geographic region, DM duration, and DM end-segment organ disease (ICD9-CM code 250.1-9) are listed as potential interference factors. The geographical area was chosen because its risk of RA was found to be relevant in previous studies. In addition, DM duration and DM end-segment organ disease represent the severity of DM. DM duration is defined as the period from the date of initiation of the antidiabetic agent to the date of the index. Other interference factors include the Charlson sympathy index (CCI) rewritten by Deyo et al (Deyo RA, Cherkin DC, Ciol MA. Adaptation a clinical compliance index for use with ICD-9-CM acquired patients. J Clin epidemic. 1992; 45(6): 613-.
[ results ]
From the above statistics, there were a total of 723 RA patients (age 16 years) as RA cases and 7,230 matched sub-RA patients as non-RA control groups (see Table 1 below). The ratio of female to male was 2.5: 1, the mean age (+ -SD) of cases was 61.7 (+ -10.8) years, and the control was 61.8 (+ -10.5) years. The clinical characteristics of the RA case and the non-RA control group were compared in table 2 below. The ratio of the case using metformin, Thiazolidinedione (TZD), insulin and sulfonylurea/glinide was higher than that of the control group.
In Table 3 below, after adjustment of the potential interference factors, the risk of RA was lower for acarbose users administered more than 16,950mg per year compared to non-users (OR, 0.60; 95% CI, 0.41-0.89); insulin use is another protective factor for the risk of RA (OR, 0.62; 95% CI, 0.45-0.87); significant risk factors for the development of RA include the use of metformin (OR, 1.26; 95% CI, 1.06-1.49), longer DM duration (OR, 1.22; 95% CI, 1.18-1.27 per year of increase), the development of DM end-segment organ disease (OR, 2.67; 95% CI, 2.23-3.19), and CCI (OR, 1.281; 95% CI, 1.26-1.31).
TABLE 1-basic characteristics of RA cases and matched non-RA control groups
Abbreviations: RA-rheumatoid arthritis; SD-standard deviation, unless otherwise indicated,
percentages are included after each value in parentheses.
TABLE 2 clinical characteristics of the-RA cases and non-RA control tissues
Data collected for the year before the date of the pointer
Data show mean. + -. standard deviation
Patients receive antibiotic treatment or periodontal treatment other than scaling, or scaling twice a year
Abbreviations: RA-rheumatoid arthritis; ICD9-CM, international classification of disease, 9 th edition,
clinical revision; unless otherwise indicated, percentages are included after each numerical value in parentheses.
TABLE 3 Single and multiple variable adjustment odds ratio 95% confidence intervals relating rheumatoid arthritis risk to newly treated diabetic variables
*P=0.079,#p=0.047.
From the above, it can be seen that patients with DM are at a reduced risk of developing RA if they are administered more than 16,950mg acarbose per year.
Example 2 confirmation of acarbose treatment of rheumatoid arthritis in mouse experiments
[ collagen-induced arthritis in mice and treatment with acarbose ]
Collagen-induced arthritis (collagen-induced arthritis CIA) was performed on DBA/1(6 to 8 weeks) mice according to conventional methods (Inglis JJ, Simalyte E, McCann FE, Criado G, Williams RO. protocol for the induction of arthritis in C57 BL/6. mic. Nat. protocol.2008; 3(4): 612-. Acarbose (DXM, Sigma-Aldrich) was dissolved and diluted with water; mice were randomly divided into three groups, and given acarbose at a dose of 500mg/kg/day, acarbose at a dose of 100mg/kg/day, and water as control groups, twice daily on days 7 to 38 after the first immunization; clinical characterization of severity of arthritis in the foot soles of mice was evaluated in a double-blind manner using a conventional scoring system (Zhou R, Tang W, Ren YX, et al (5R) -5-hydroxytriptolide characterized collagen-induced arthritis in DBA/1-blood vision rendering interference-gamma production and related signaling. J Pharm Exp. Ther.2006; 318(1): 35-44).
[ histopathological analysis ]
Representative ankle joints were obtained from three mice per group on day 38, fixed in paraffin, decalcified and embedded. Each joint was sectioned (5M) and stained with hematoxylin and eosin (H & E), followed by microscopic examination according to conventional methods (Wooley pH. Collagen-induced arthritis in the mouse. methods Enzymol.1988; 162: 361-373.). Histopathological changes of synovial hyperplasia, cell infiltration, cartilage destruction and bone erosion were blindly graded by the pathologist and given in 0-3 points, 0 according to the following criteria: no change; 1: mild changes; 2: moderate changes; 3: the severity changes.
[ measurement of cytokine content ]
Mouse paw tissue was collected on day 38 for each group and frozen in liquid nitrogen, and samples were taken up with PBS in protease inhibitor and homogenized in a tissue plastometer. The homogenate was centrifuged for 30 minutes and the supernatant was collected and diluted to 1mg/ml tissue protein as stock. The contents of TNF-a, IL-1b, IL-6, IFN-g, IL-17, IL-10 and TGF-b (R & D Systems) were determined using an ELISA kit (Peprotech).
[ analysis of anti-collagen type II IgG antibody production ]
Mice were bled on day 38 after CII immunization and their sera were analyzed by ELISA titration using anti-CII IgG antibodies. Briefly, each well of an ELISA microplate (Thermo Fisher Scientific, NY, USA) was coated with 10. mu.g/200 ml of type II chicken collagen and incubated overnight at 4 ℃. To avoid non-specific binding, antibodies were washed and blocked with 3% Bovine Serum Albumin (BSA) (BD Biosciences) Tris buffer; the sera to be tested were serially diluted and added to the well plate for overnight incubation at 4 ℃. After 5 to 7 washes, bound IgG was detected as a secondary antibody by dilution 1:5000 with HRP-conjugated sheep anti-mouse IgG; after washing, the well plates were reacted with ABTS (Roche Diagnostic Systems, IN, USA) as a substrate and with H2SO4The reaction was stopped and absorbance measured at 450nm with an ELISA reader.
[ cell proliferation ]
On day 38 after immunization, the inguinal lymph node of CIA mice was cultured with CII full-variable medium at 40. mu.g/ml for 3 days. Before 18 hours of termination of the culture, 1. mu. Ci of3H]]Thymidine was pulsed into each plate and cell proliferation was measured in counts per minute (cpm) by a Matrix 96 direct ionization beta counter (Packard Instrument, Meridian, CT).
[ results ]
CIA has been widely used to cause arthritis that exhibits the pathological features of human RA. First it was investigated whether acarbose could prevent the progression of CIA in the DBA/1 mouse model. As shown in fig. 1, CIA mice given water (control group) had severe CIA at day 24. However, mice treated with 500mg/kg/day acarbose had a significant reduction in the incidence of CIA (fig. 1A) and the number of diseased soles (fig. 1B) and were visually confirmed to have less severe swelling, erythema and joint stiffness in the hind soles (fig. 1C) and an arthritic score (fig. 1D) compared to the control group; oral treatment with acarbose at 100mg/kg/day had no significant effect on the development and severity of CIA.
To further assess arthritis, histological (H & E) studies of the ankle joints of mice were performed at the end of the experiment. Consistent with the observed reduced sole swelling and clinical score, mice administered 500mg/kg/day acarbose had a significant reduction in: infiltration of inflammatory cells, synovial hyperplasia, and bone erosion of the ankle joint (fig. 1E-F). The amount of selective cytokines in the paw tissues and serum was then determined by ELISA and, as shown in FIGS. 2A and 2B, the inflammatory cytokines such as TNF-alpha, IL-6 and IL-17 were significantly reduced in the paw tissues and serum of acarbose-treated mice as compared to control CIA mice. These results show that oral administration of acarbose is effective in preventing the development of CIA and inhibiting local inflammation of joints.
In the CIA model, antibodies as well as T cell responses were associated with disease etiology after immunization with type II collagen. Thus, C-II specific antibodies in serum and CII specific T lymphocyte expansion in lymph nodes were further measured. As shown in FIG. 3A, treatment with 500mg/kg/day acarbose resulted in a significant decrease in anti-CII IgG production, and furthermore, lymph node cells obtained from acarbose-treated mice showed a significant decrease in CII antigen-stimulated proliferation (FIG. 3B), and decreased IL-17 and IFN-production from collagen-stimulated lymph node cells, as compared to cells obtained from control group CIA mice. In contrast, L-10 had increased expression in acarbose-treated CIA mice (FIG. 3C). These data show that the immune response, whether humoral or cellular, is inhibited by acarbose treatment.
Example 3 comparison of CIA mouse experiments with acarbose and tofacitinib administered individually and in combination
[ evaluation of the efficacy of tofacitinib at various doses in CIA mice ]
Using CIA mice as in example 2, the mice were randomized into four groups, given 1mg/kg/day, 5mg/kg/day, 25mg/kg/day doses of tofacitinib and water as control groups, twice daily on days 7 to 38 after the first immunization; clinical characterization of the severity of arthritis in the mouse paw was done using a known scoring system.
[ results ]
As shown in fig. 4A, the higher the dose, the better the clinical characterization of the therapeutic effect on CIA mice using tofacitinib, a known therapeutic agent for rheumatoid arthritis.
[ evaluation of efficacy of acarbose 500mg/kg/day in combination with tofacitinib 1mg/kg/day in CIA mice ]
Using CIA mice as in example 2, the mice were randomized into four groups, given 1mg/kg/day tofacitinib, 500mg/kg/day acarbose, 1mg/kg/day tofacitinib, and 500mg/kg/day acarbose, respectively, and water as a control group, twice daily on days 7 to 38 after the first immunization; clinical characterization of the severity of arthritis in the mouse paw was done using a known scoring system.
[ results ]
As shown in FIG. 4B, the dose of acarbose generally used for the treatment of type II diabetes was more effective than the dose of tofacitinib 1mg/kg/day generally used for the treatment of rheumatoid arthritis; and after the two are used together, the effect is better than that of single administration.
[ evaluation of efficacy of acarbose 500mg/kg/day in combination with tofacitinib 5mg/kg/day in CIA mice ]
[ results ]
As shown in FIG. 4C, both acarbose 500mg/kg/day and tofacitinib 5mg/kg/day can be used for the treatment of rheumatoid arthritis; and after the two are combined for use, the effect is more obvious.
Example 4 mouse experiments with Imquimod induced psoriasis by acarbose administration
[ mice with induction of psoriasis and administration method ]
Tinea pedis mice were obtained by conventional techniques, and briefly described, after hair removal from the back of the mice, 62.5mg of commercially available Imiquimod (IMQ) ointment ((Aldara; 3M Pharmaceuticals) was applied to the back of the mice continuously daily for 6 days, 7 days, after the mice were photographed and sacrificed, the back skin was removed and subjected to slicing analysis, acarbose was orally administered daily until the end of the experiment (6 days) at the beginning of application of Imiquimod (IMQ) ointment, and the clinical scores were either 500mg/kg or 100 mg/kg., respectively, based on clinical criteria such as erythema (erythasia Area and susceptibility Index (PASI), and were classified into 5 grades, 0 representing no change, and 1 to 4, with higher grades representing severe erythema and desquamation (scaling).
[ results ]
As can be seen in FIGS. 5A and 5B, mice with Imiquimod (IMQ)62.5mg/kg/day induced psoriasis had significant therapeutic effect after administration of 500mg/kg/day acarbose.
[ histopathological analysis ]
Dorsal skin tissue from one mouse per group on day 7 was fixed, decalcified and embedded in paraffin. After sectioning (5M), the sections were observed under a microscope by hematoxylin and eosin staining (H & E). As shown in fig. 6. According to the slicing results, it was found that 500mg/kg of acarbose significantly slowed down Imiquimod (IMQ) -induced mice, resulting in epidermal hypertrophy (acanthosis), thickening of stratum corneum, residual nuclei, and poor hornification (parakeratosis).
The comprehensive experiments show that acarbose can be used for treating immune inflammation diseases such as rheumatoid arthritis, psoriasis and the like, and the efficacy of adjusting and combining IL-17 is proved, so that acarbose can be more widely used for the immune inflammation diseases related to IL-17.
Claims (3)
1. A pharmaceutical composition for treating rheumatoid arthritis, comprising: the pharmaceutical composition comprises acarbose and tofacitinib.
2. The pharmaceutical composition for the treatment of rheumatoid arthritis according to claim 1, wherein: in the form of tablets or capsules.
3. The pharmaceutical composition for the treatment of rheumatoid arthritis according to claim 2, wherein: the pharmaceutical composition is formulated for local administration or systemic administration.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/080849 WO2016192098A1 (en) | 2015-06-05 | 2015-06-05 | Pharmaceutical composition containing acarbose and use thereof in regulating immunization |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107106583A CN107106583A (en) | 2017-08-29 |
CN107106583B true CN107106583B (en) | 2021-04-13 |
Family
ID=57439955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580063655.6A Expired - Fee Related CN107106583B (en) | 2015-06-05 | 2015-06-05 | Pharmaceutical compositions comprising acarbose and their use for immunomodulation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107106583B (en) |
WO (1) | WO2016192098A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026639A2 (en) * | 1999-10-08 | 2001-04-19 | Novartis Ag | Pharmaceutical composition of ateglinide and another antidiabeticagent |
CN1823795A (en) * | 2005-12-30 | 2006-08-30 | 刘展欣 | Medicinal composition for treating diabetes and its preparation method |
GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
-
2015
- 2015-06-05 CN CN201580063655.6A patent/CN107106583B/en not_active Expired - Fee Related
- 2015-06-05 WO PCT/CN2015/080849 patent/WO2016192098A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026639A2 (en) * | 1999-10-08 | 2001-04-19 | Novartis Ag | Pharmaceutical composition of ateglinide and another antidiabeticagent |
CN1823795A (en) * | 2005-12-30 | 2006-08-30 | 刘展欣 | Medicinal composition for treating diabetes and its preparation method |
GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
Non-Patent Citations (2)
Title |
---|
Is acarbose an effective drug for treating patients with cirrhosis and hepatic encephalopathy?;Gentile S等;《NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY》;20050630;第2卷(第6期);第264-265页 * |
诺和锐30联用阿卡波糖治疗LADA的临床疗效观察;罗亚芳等;《中国现代医生》;20100131;第48卷(第3期);第133-134页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016192098A1 (en) | 2016-12-08 |
CN107106583A (en) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Knobler et al. | European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes | |
Hon et al. | Chronic urticaria: an overview of treatment and recent patents | |
Weinblatt et al. | Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve‐week, randomized, placebo‐controlled trial | |
ES2476368T3 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
KR101611824B1 (en) | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response | |
Li et al. | Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation | |
JP5117189B2 (en) | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases | |
KR20140038378A (en) | Baclofen and acamprosate based therapy of neurogical disorders | |
KR20170003527A (en) | Compositions of pentosan polysulfate salts for oral administration and methods of use | |
CN106488769A (en) | For treating Fibrotic Sai Nikeweiluo | |
JP6434487B2 (en) | Desethylhydroxychloroquine for the treatment of diseases with inflammation | |
KR20150013658A (en) | Use of High Dose Laquinimod for Treating Multiple Sclerosis | |
CA3213864A1 (en) | Dosing regimen of tradipitant | |
US20240016735A1 (en) | Ionic liquids for drug delivery | |
Thurmond et al. | Peripheral Neuronal Mechanism of Itch | |
EP1401415B1 (en) | Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases | |
US20220354834A1 (en) | Methods and materials for treating neurotoxicity | |
CN114364681A (en) | Methods of treating MK2 mediated disorders | |
JP2020500165A (en) | Composition comprising anti-A beta protofibril antibody and beta-secretase BACE1 inhibitor for treating Alzheimer's disease | |
Brolin et al. | Chronic administration of morphine using mini-osmotic pumps affects spatial memory in the male rat | |
CN107106583B (en) | Pharmaceutical compositions comprising acarbose and their use for immunomodulation | |
Hetze et al. | Taste-immune associative learning amplifies immunopharmacological effects and attenuates disease progression in a rat glioblastoma model | |
EP3376869B1 (en) | Treatment of autoimmune disease | |
HUE032356T2 (en) | New therapeutic approaches for treating neuroinflammatory conditions | |
TWI554272B (en) | Pharmaceutical composition comprising acarbose and its use for immunomodulatory |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210413 |